Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks

Psychoneuroendocrinology

Volumn 38, Issue 12, 2013, Pages 2952-2961

  Hill, Matthew N ^a,b   Bierer, Linda M ^c   Makotkine, Iouri ^c   Golier, Julia A ^c   Galea, Sandro ^d   McEwen, Bruce S ^b   Hillard, Cecilia J ^e   Yehuda, Rachel ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b ROCKEFELLER UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Columbia Mailman School of Public Health ^*  (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

2 Arachidonoylglycerol; Anandamide; Anxiety; Cortisol; Endocannabinoid; HPA axis; N arachidonylethanolamine; PTSD; Stress; Trauma

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; GLUCOCORTICOID; HYDROCORTISONE; N OLEOYLETHANOLAMINE; PALMIDROL;

ADULT; ALCOHOL ABUSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSTHYMIA; ENVIRONMENTAL EXPOSURE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INTERRATER RELIABILITY; MAJOR DEPRESSION; MALE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SELF REPORT; SEXUAL ABUSE; STRESS; TERRORISM;

2-ARACHIDONOYLGLYCEROL; ANANDAMIDE; ANXIETY; CORTISOL; ENDOCANNABINOID; HPA AXIS; N-ARACHIDONYLETHANOLAMINE; PTSD; STRESS; TRAUMA;

AGED; ALCOHOLISM; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; ETHANOLAMINES; ETHNIC GROUPS; FEMALE; GLYCERIDES; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OLEIC ACIDS; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES; PSYCHIATRIC STATUS RATING SCALES; SEX CHARACTERISTICS; STRESS DISORDERS, POST-TRAUMATIC; TERRORISM;

EID: 84888299927     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.08.004     Document Type: Article

References (57)

1. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. 2008, 108:1687-1707.
2. Atsak P., Hauer D., Campolongo P., Schelling G., McGaugh J.L., Roozendaal B. Glucocorticoids interact with the hippocampal endocannabinoid system in impairing retrieval of contextual fear memory. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3504-3509.
3. Baker D.G., Ekhator N.N., Kasckow J.W., Hill K.K., Zoumakis E., Dashevsky B.A., Chrousos G.P., Geracioti T.D. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation 2001, 9:209-217.
4. Bellocchio L., Soria-Gomez E., Quarta C., Metna-Laurent M., Cardinal P., Binder E., Cannich A., Delamarre A., et al. Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4786-4791.
5. Beyer C.E., Dwyer J.M., Piesla M.J., Platt B.J., Shen R., Rahman Z., Chan K., Manners M.T., et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol. Dis. 2010, 39:148-155.
6. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Gusman F.D., Charney D.S., Keane T.M. The development of a Clinician-Administered PTSD Scale. J. Trauma. Stress 1995, 8:75-90.
7. Breslau N., Davis G.C., Peterson E.L., Schultz L.R. A second look at comorbidity in victims of trauma: the post-traumatic stress disorder-major depression connection. Biol. Psychiatry 2000, 48:902-909.
8. Campolongo P., Roozendaal B., Trezza V., Hauer D., Schelling G., McGaugh J.L., Cuomo V. Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4888-4893.
9. Chhatwal J.P., Davis M., Maguschak K.A., Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005, 30:516-524.
10. Chouker A., Kaufmann I., Kreth S., Hauer D., Feuerecker M., Thieme D., Vogeser M., Thiel M., Schelling G. Motion sickness, stress and the endocannabinoid system. PLoS ONE 2010, 5:e10752.
11. Cohen H., Liu T., Kozlovsky N., Kaplan Z., Zohar J., Mathe A.A. The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology 2012, 37:350-363.
12. Di S., Malcher-Lopes R., Halmos K.C., Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 2003, 23:4850-4857.
13. Dlugos A., Childs E., Stuhr K.L., Hillard C.J., de Wit H. Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 2012, 37:2416-2427.
14. Evanson N.K., Tasker J.G., Hill M.N., Hillard C.J., Herman J.P. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology 2010, 151:4811-4819.
15. Foa E.B., Riggs D.S., Dancu C.V., Rothbaum B.O. Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. J. Trauma. Stress 1993, 6:459-473.
16. Fu S.S., McFall M., Saxon A.J., Beckham J.C., Carmody T.P., Baker D.G., Joseph A.M. Post-traumatic stress disorder and smoking: a systematic review. Nicotine Tob. Res. 2007, 9:1071-1084.
17. Gamber K.M., MacArthur K.M., Westfall T.C. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005, 49:646-652.
18. Gunduz-Cinar O., Macpherson K.P., Cinar R., Gamble-George J., Sugden K., Williams B., Godlweski G., Ramikie T.S., et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 2013, 18:813-823.
19. Hansen H.S. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp. Neurol. 2010, 224:48-55.
20. Hariri A.R., Gorka A., Hyde L.W., Kimak M., Halder I., Ducci F., Ferrell R.E., Goldman D., Manuck S.B. Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol. Psychiatry 2009, 66:9-16.
21. Hauer D., Weis F., Campolongo P., Schopp M., Beiras-Fernandez A., Strewe C., Giehl M., Toth R., et al. Glucocorticoid-endocannabinoid interaction in cardiac surgical patients: relationship to early cognitive dysfunction and late depression. Rev. Neurosci. 2012, 23:681-690.
22. Hauer D., Schelling G., Gola H., Campolongo P., Morath J., Roozendaal B., Hamuni G., Karabatsiakis A., et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS ONE 2013, 8:e62741.
23. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord. Drug Targets 2009, 8:451-458.
24. Hill M.N., McEwen B.S. Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:791-797.
25. Hill M.N., Tasker J.G. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 2012, 204:5-16.
26. Hill M.N., Miller G.E., Ho W.S., Gorzalka B.B., Hillard C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41:48-53.
27. Hill M.N., McLaughlin R.J., Morrish A.C., Viau V., Floresco S.B., Hillard C.J., Gorzalka B.B. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009, 34:2733-2745.
28. Hill M.N., Miller G.E., Carrier E.J., Gorzalka B.B., Hillard C.J. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34:1257-1262.
29. Hill M.N., Karatsoreos I.N., Hillard C.J., McEwen B.S. Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology 2010, 35:1333-1338.
30. Hill M.N., McLaughlin R.J., Bingham B., Shrestha L., Lee T.T., Gray J.M., Hillard C.J., et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9406-9411.
31. Hill M.N., McLaughlin R.J., Pan B., Fitzgerald M.L., Roberts C.J., Lee T.T., Karatsoreos I.N., Mackie K., et al. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J. Neurosci. 2011, 31:10506-10515.
32. Hillard C.J., Weinlander K.M., Stuhr K.L. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012, 204:207-229.
33. Ishac E.J., Jiang L., Lake K.D., Varga K., Abood M.E., Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 1996, 118:2023-2028.
34. Krystal J.H., Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Res. 2009, 1293:13-23.
35. Mangieri R.A., Hong K.I., Piomelli D., Sinha R. An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl.) 2009, 205:63-72.
36. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
37. McPartland J.M., Giuffrida A., King J., Skinner E., Scotter J., Musty R.E. Cannabimimetic effects of osteopathic manipulative treatment. J. Am. Osteopath. Assoc. 2005, 105:283-291.
38. Morgan C.A., Wang S., Southwick S.M., Rasmusson A., Hazlett G., Hauger R.L., Charney D.S. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry 2000, 47:902-909.
39. Neumeister A. The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD. Depress. Anxiety 2013, 30:93-96.
40. Neumeister A., Normandin M.D., Pietrzak R.H., Piomelli D., Zheng M.Q., Gujarro-Anton A., Potenza M.N., Bailey C.R., et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry 2013, (in press).
41. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145:5431-5438.
42. Patel S., Carrier E.J., Ho W.S., Rademacher D.J., Cunningham S., Reddy D.S., Falck J.R., Cravatt B.F., Hillard C.J. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J. Lipid Res. 2005, 46:342-349.
43. Patel S., Roelke C.T., Rademacher D.J., Hillard C.J. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur. J. Neurosci. 2005, 21:1057-1069.
44. Pervanidou P., Chrousos G.P. Neuroendocrinology of post-traumatic stress disorder. Prog. Brain Res. 2010, 182:149-160.
45. Plantinga L., Bremner J.D., Miller A.H., Jones D.P., Veledar E., Goldberg J., Vaccarino V. Association between posttraumatic stress disorder and inflammation: a twin study. Brain Behav. Immun. 2013, 30:125-132.
46. Plendl W., Wotjak C.T. Dissociation of within- and between-session extinction of conditioned fear. J. Neurosci. 2010, 30:4990-4998.
47. Rasmusson A.M., Hauger R.L., Morgan C.A., Bremner J.D., Charney D.S., Southwick S.M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol. Psychiatry 2000, 47:526-539.
48. Riebe C.J., Wotjak C.T. Endocannabinoids and stress. Stress 2011, 14:384-397.
49. Sah R., Ekhator N.N., Strawn J.R., Sallee F.R., Baker D.G., Horn P.S., Geracioti T.D. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol. Psychiatry 2009, 66:705-707.
50. Sajdyk T.J., Johnson P.L., Leitermann R.J., Fitz S.D., Dietrich A., Morin M., Gehlert D.R., Urban J.H., Shekhar A. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J. Neurosci. 2008, 28:893-903.
51. Sarapas C., Cai G., Bierer L.M., Golier J.A., Galea S., Ising M., Rein T., Schmeidler J., et al. Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. Dis. Markers 2011, 30:101-110.
52. Spitzer R.L., Williams J.B.W., Gibbon M. Structured Clinical Interview for DSM-IV (SCID) 1995, New York State Psychiatric Institute Biometrics Research.
53. Spivak B., Shohat B., Mester R., Avraham S., Gil-Ad I., Bleich A., Valevski A., Weizman A. Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. Biol. Psychiatry 1997, 42:345-348.
54. Srivastava R.J., Lutz B. Dysregulation of hypothalamic-pituitary-adrenal axis in mice lacking CB1 receptors in adrenergic and noradrenergic neurons. P1-28, 22nd Annual Symposium of the International Cannabinoid Research Society 2012.
55. Yehuda R. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann. N.Y. Acad. Sci. 2009, 1179:56-69.
56. Yehuda R., Brand S., Yang R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry 2006, 59:660-663.
57. Yehuda R., Cai G., Golier J.A., Sarapas C., Galea S., Ising M., Rein T., Schmeidler J., et al. Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. Biol. Psychiatry 2009, 66:708-711.